|
1
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263.
2024.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Duma N, Santana-Davila R and Molina JR:
Non-small cell lung cancer: Epidemiology, screening, diagnosis, and
treatment. Mayo Clin Proc. 94:1623–1640. 2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Siegel RL, Kratzer TB, Giaquinto AN, Sung
H and Jemal A: Cancer statistics, 2025. CA Cancer J Clin. 75:10–45.
2025.PubMed/NCBI View Article : Google Scholar
|
|
4
|
National Cancer Institute: Cancer Stat
Facts: Lung and Bronchus Cancer. Surveillance, Epidemiology, and
End Results Program, 2025. National Cancer Institute, Bethesda, MD,
2025. Accessed on May 10, 2026. https://seer.cancer.gov/statfacts/html/lungb.html.
|
|
5
|
Garg P, Htay ZW, Shah M, Bhatti S, Pedroza
J, Crotty R and Aggarwal C: Advances in non-small cell lung cancer:
Current insights and future directions. J Clin Med.
13(4189)2024.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Lisberg A, Cummings A, Goldman JW,
Bornazyan K, Reese N, Wang T, Coluzzi P, Ledezma C, Mendenhall M,
Hunt J, et al: A phase II study of Pembrolizumab in EGFR-mutant,
PD-L1+, tyrosine kinase inhibitor Naïve patients with advanced
NSCLC. J Thorac Oncol. 13:1138–1145. 2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Peng S, Wang R, Zhang X, Ma Y, Zhong L, Li
K, Nishiyama A, Arai S, Yano S and Wang W: EGFR-TKI resistance
promotes immune escape in lung cancer via increased PD-L1
expression. Mol Cancer. 18(165)2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Forde PM, Spicer J, Lu S, Provencio M,
Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson
SJ, et al: Neoadjuvant nivolumab plus chemotherapy in resectable
lung cancer. N Engl J Med. 386:1973–1985. 2022.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Reck M, Rodríguez-Abreu D, Robinson AG,
Hui R, Csoszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe
S, et al: Five-year outcomes with pembrolizumab versus chemotherapy
for metastatic Non-small-cell lung cancer With PD-L1 tumor
proportion score ≥ 50. J Clin Oncol. 39:2339–2349. 2021.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Garon EB, Rizvi NA, Hui R, Leighl N,
Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L,
et al: Pembrolizumab for the treatment of non-small-cell lung
cancer. N Engl J Med. 372:2018–2028. 2015.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Schoenfeld AJ and Hellmann MD: Acquired
resistance to immune checkpoint inhibitors. Cancer Cell.
37:443–455. 2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Dai Y, Wu Z, Lin X, Hu T and Zhou H: Role
of the TME in immune checkpoint blockade resistance of non-small
cell lung cancer. Cancer Drug Resist. 7(52)2024.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Binnewies M, Roberts EW, Kersten K, Chan
V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI,
Ostrand-Rosenberg S, Hedrick CC, et al: Understanding the tumor
immune microenvironment (TIME) for effective therapy. Nat Med.
24:541–550. 2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Konen JM, Wu H and Gibbons DL: Immune
checkpoint blockade resistance in lung cancer: emerging mechanisms
and therapeutic opportunities. Trends Pharmacol Sci. 45:520–536.
2024.PubMed/NCBI View Article : Google Scholar
|
|
15
|
de Visser KE and Joyce JA: The evolving
tumor microenvironment: From cancer initiation to metastatic
outgrowth. Cancer Cell. 41:374–403. 2023.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Zhang Q and Sioud M: Tumor-associated
macrophage subsets: Shaping polarization and targeting. Int J Mol
Sci. 24(7493)2023.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Mantovani A, Allavena P, Marchesi F and
Garlanda C: Macrophages as tools and targets in cancer therapy. Nat
Rev Drug Discov. 21:799–820. 2022.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Shabo I and Svanvik J: Expression of
macrophage antigens by tumor cells. Adv Exp Med Biol. 714:141–150.
2011.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Cheng S, Li Z, Gao R, Xing B, Gao Y, Yang
Y, Qin S, Zhang L, Ouyang H, Du P, et al: A pan-cancer single-cell
transcriptional atlas of tumor infiltrating myeloid cells. Cell.
184:792–809.e23. 2021.PubMed/NCBI View Article : Google Scholar
|
|
20
|
He Z and Zhang S: Tumor-Associated
macrophages and their functional transformation in the hypoxic
tumor microenvironment. Front Immunol. 12(741305)2021.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Veglia F, Sanseviero E and Gabrilovich DI:
Myeloid-derived suppressor cells in the era of increasing myeloid
cell diversity. Nat Rev Immunol. 21:485–498. 2021.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Li K, Shi H, Zhang B, Ou X, Ma Q, Chen Y,
Shu P, Li D, Wang Y and Wang X: Myeloid-derived suppressor cells as
immunosuppressive regulators and therapeutic targets in cancer.
Signal Transduct Target Ther. 6(362)2021.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Togashi Y, Shitara K and Nishikawa H:
Regulatory T cells in cancer immunosuppression-implications for
anticancer therapy. Nat Rev Clin Oncol. 16:356–371. 2019.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Hsieh CS and Bautista JL: Sliding
set-points of immune responses for therapy of autoimmunity. J Exp
Med. 207:1819–1823. 2010.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Gu D, Ao X, Yang Y, Chen Z and Xu X:
Soluble immune checkpoints in cancer: Production, function and
biological significance. J Immunother Cancer. 6(132)2018.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Bergers G, Brekken R, McMahon G, Vu TH,
Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z and
Hanahan D: Matrix metalloproteinase-9 triggers the angiogenic
switch during carcinogenesis. Nat Cell Biol. 2:737–744.
2000.PubMed/NCBI View
Article : Google Scholar
|
|
27
|
Masson V, de la Ballina LR, Munaut C,
Wielockx B, Jost M, Maillard C, Blacher S, Bajou K, Itoh T, Itohara
S, et al: Contribution of host MMP-2 and MMP-9 to promote tumor
vascularization and invasion of malignant keratinocytes. FASEB J.
19:234–236. 2005.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Wen J, Yu JZ, Liu C, Ould Ismail AAO and
Ma W: Exploring the molecular tumor microenvironment and
translational biomarkers in brain metastases of Non-small-cell lung
cancer. Int J Mol Sci. 25(2044)2024.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Bruni D, Angell HK and Galon J: The immune
contexture and Immunoscore in cancer prognosis and therapeutic
efficacy. Nat Rev Cancer. 20:662–680. 2020.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Galon J and Bruni D: Approaches to treat
immune hot, altered and cold tumours with combination
immunotherapies. Nat Rev Drug Discov. 18:197–218. 2019.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Andrews LP, Marciscano AE, Drake CG and
Vignali DAA: LAG3 (CD223) as a cancer immunotherapy target. Immunol
Rev. 276:80–96. 2017.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Freeman GJ, Casasnovas JM, Umetsu DT and
DeKruyff RH: TIM genes: A family of cell surface phosphatidylserine
receptors that regulate innate and adaptive immunity. Immunol Rev.
235:172–189. 2010.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Chauvin JM and Zarour HM: TIGIT in cancer
immunotherapy. J Immunother Cancer. 8(e000957)2020.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Ge Z, Peppelenbosch MP, Sprengers D and
Kwekkeboom J: TIGIT, the next step towards successful combination
immune checkpoint therapy in cancer. Front Immunol.
12(699895)2021.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Noman MZ, Desantis G, Janji B, Hasmim M,
Karray S, Dessen P, Bronte V and Chouaib S: PD-L1 is a novel direct
target of HIF-1α, and its blockade under hypoxia enhanced
MDSC-mediated T cell activation. J Exp Med. 211:781–790.
2014.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Watson MJ, Vignali PDA, Mullett SJ,
Overacre-Delgoffe AE, Peralta RM, Grebinoski S, Menk AV,
Rittenhouse NL, DePeaux K, Whetstone RD, et al: Metabolic support
of tumour-infiltrating regulatory T cells by lactic acid. Nature.
591:645–651. 2021.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Munn LL and Jain RK: Vascular regulation
of antitumor immunity. Science. 365:544–545. 2019.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Torrejon DY, Galvez M, Abril-Rodriguez G,
Campbell KM, Medina E, Vega-Crespo A, Kalbasi A, Comin-Anduix B and
Ribas A: Antitumor immune responses in B2M-deficient cancers.
Cancer Immunol Res. 11:1642–1655. 2023.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Dhatchinamoorthy K, Colbert JD and Rock
KL: Cancer immune evasion through loss of MHC class I antigen
presentation. Front Immunol. 12(636568)2021.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Zheng J, Deng Y, Huang B and Chen X:
Prognostic implications of STK11 with different mutation status and
its relationship with tumor-infiltrating immune cells in non-small
cell lung cancer. Front Immunol. 15(1387896)2024.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Zhou F, Qiao M and Zhou C: The
cutting-edge progress of immune-checkpoint blockade in lung cancer.
Cell Mol Immunol. 18:279–293. 2021.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Calvayrac O, Mazières J, Figarol S,
Marty-Detraves C, Raymond-Letron I, Bousquet E, Farella M,
Clermont-Taranchon E, Milia J, Rouquette I, et al: The RAS-related
GTPase RHOB confers resistance to EGFR-tyrosine kinase inhibitors
in non-small-cell lung cancer via an AKT-dependent mechanism. EMBO
Mol Med. 9:238–250. 2017.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Kumagai S, Togashi Y, Kamada T, Sugiyama
E, Nishinakamura H, Takeuchi Y, Vitaly K, Itahashi K, Maeda Y,
Matsui S, et al: The PD-1 expression balance between effector and
regulatory T cells predicts the clinical efficacy of PD-1 blockade
therapies. Nat Immunol. 21:1346–1358. 2020.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Hakozaki T, Richard C, Elkrief A, Hosomi
Y, Benlaïfaoui M, Mimpen I, Terrisse S, Derosa L, Zitvogel L, Routy
B and Okuma Y: The Gut Microbiome Associates with Immune Checkpoint
Inhibition Outcomes in Patients with Advanced Non-Small Cell Lung
Cancer. Cancer Immunol Res. 8:1243–1250. 2020.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Li H, Zhang L, Yang F, Zhao R, Li X and Li
H: Impact of concomitant medications on the efficacy of immune
checkpoint inhibitors: An umbrella review. Front Immunol.
14(1218386)2023.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Routy B, Le Chatelier E, Derosa L, Duong
CPM, Alou MT, Daillere R, Fluckiger A, Messaoudene M, Rauber C,
Roberti MP, et al: Gut microbiome influences efficacy of PD-1-based
immunotherapy against epithelial tumors. Science. 359:91–97.
2018.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Duttagupta S, Hakozaki T, Routy B and
Messaoudene M: The gut microbiome from a biomarker to a novel
therapeutic strategy for immunotherapy response in patients with
lung cancer. Curr Oncol. 30:9406–9427. 2023.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Spencer CN, McQuade JL, Gopalakrishnan V,
McCulloch JA, Vetizou M, Cogdill AP, Khan MAW, Zhang X, White MG,
Peterson CB, et al: Dietary fiber and probiotics influence the gut
microbiome and melanoma immunotherapy response. Science.
374:1632–1640. 2021.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Kasprzak A: The role of tumor
microenvironment cells in colorectal cancer (CRC) cachexia. Int J
Mol Sci. 22(1565)2021.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Ribas A and Wolchok JD: Cancer
immunotherapy using checkpoint blockade. Science. 359:1350–1355.
2018.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Wei SC, Duffy CR and Allison JP:
Fundamental mechanisms of immune checkpoint blockade therapy.
Cancer Discov. 8:1069–1086. 2018.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Hellmann MD, Paz-Ares L, Bernabe Caro R,
Zurawski B, Kim SW, Carcereny Costa E, Park K, Alexandru A,
Lupinacci L, de la Mora Jimenez E, et al: Nivolumab plus ipilimumab
in advanced non-small-cell lung cancer. N Engl J Med.
381:2020–2031. 2019.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Cheng L, Chen L, Shi Y, Gu W, Ding W,
Zheng X, Liu Y, Jiang J and Zheng Z: Efficacy and safety of
bispecific antibodies vs. immune checkpoint blockade combination
therapy in cancer: A real-world comparison. Mol Cancer.
23(77)2024.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Rodriguez-Abreu D, Johnson ML, Hussein MA,
Cobo M, Patel AJ, Secen NM, Lee KH, Massuti B, Hiret S, Yang JC, et
al: Primary analysis of a randomized, double-blind, phase II study
of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab
(atezo) versus placebo plus atezo as first-line (1L) treatment in
patients with PD-L1-selected NSCLC (CITYSCAPE). J Clin Oncol.
38:9503. 2020.
|
|
55
|
Roche: Roche reports update on Phase III
SKYSCRAPER-01 study results, 2024. Accessed June on 24, 2026.
https://www.roche.com/media/releases/med-cor-2024-11-26.
|
|
56
|
Tawbi HA, Schadendorf D, Lipson EJ,
Ascierto PA, Matamala L, Castillo Gutierrez E, Rutkowski P, Gogas
HJ, Lao CD, De Menezes JJ, et al: Relatlimab and nivolumab versus
nivolumab in untreated advanced melanoma. N Engl J Med. 386:24–34.
2022.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Schöffski P, Tan DSW, Martín M,
Ochoa-de-Olza M, Sarantopoulos J, Carvajal RD, Kyi C, Esaki T,
Prawira A, Akerley W, et al: Phase I/II study of the LAG-3
inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001)
in patients with advanced malignancies. J Immunother Cancer.
10(e003776)2022.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Villaruz LC, Blumenschein GR Jr, Otterson
GA and Leal TA: Emerging therapeutic strategies for enhancing
sensitivity and countering resistance to programmed cell death
protein 1 or programmed death-ligand 1 inhibitors in non-small cell
lung cancer. Cancer. 129:1319–1350. 2023.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Koyama S, Akbay EA, Li YY, Herter-Sprie
GS, Buczkowski KA, Richards WG, Gandhi L, Redig AJ, Rodig SJ,
Asahina H, et al: Adaptive resistance to therapeutic PD-1 blockade
is associated with upregulation of alternative immune checkpoints.
Nat Commun. 7(10501)2016.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Fukumura D, Kloepper J, Amoozgar Z, Duda
DG and Jain RK: Enhancing cancer immunotherapy using
antiangiogenics: Opportunities and challenges. Nat Rev Clin Oncol.
15:325–340. 2018.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Jain RK: Antiangiogenesis strategies
revisited: From starving tumors to alleviating hypoxia. Cancer
Cell. 26:605–622. 2014.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Socinski MA, Jotte RM, Cappuzzo F, Orlandi
F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D,
Thomas CA, Barlesi F, et al: Atezolizumab for first-line treatment
of metastatic nonsquamous NSCLC. N Engl J Med. 378:2288–2301.
2018.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Reck M, Mok TSK, Nishio M, Jotte RM,
Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu
D, Moro-Sibilot D, et al: Atezolizumab plus bevacizumab and
chemotherapy in non-small-cell lung cancer (IMpower150): Key
subgroup analyses of patients with EGFR mutations or baseline liver
metastases in a randomised, open-label phase 3 trial. Lancet Respir
Med. 7:387–401. 2019.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Wallin JJ, Bendell JC, Funke R, Sznol M,
Korski K, Jones S, Hernandez G, Mier J, He X, Hodi FS, et al:
Atezolizumab in combination with bevacizumab enhances
antigen-specific T-cell migration in metastatic renal cell
carcinoma. Nat Commun. 7(12624)2016.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Yi M, Jiao D, Qin S, Chu Q, Wu K and Li A:
Synergistic effect of immune checkpoint blockade and
anti-angiogenesis in cancer treatment. Mol Cancer.
18(60)2019.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Han B, Li K, Wang Q, Zhang L, Shi J, Wang
Z, Cheng Y, He J, Shi Y, Zhao Y, et al: Effect of anlotinib as a
third-line or further treatment on overall survival of patients
with advanced non-small cell lung cancer: The ALTER 0303 phase 3
randomized clinical trial. JAMA Oncol. 4:1569–1575. 2018.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Demaria S, Golden EB and Formenti SC: Role
of local radiation therapy in cancer immunotherapy. JAMA Oncol.
1:1325–1332. 2015.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Paz-Ares L, Spira A, Raben D, Planchard D,
Cho BC, Özgüroğlu M, Daniel D, Villegas A, Vicente D, Hui R, et al:
Outcomes with durvalumab by tumour PD-L1 expression in
unresectable, stage III non-small-cell lung cancer in the PACIFIC
trial. Ann Oncol. 31:798–806. 2020.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Zhang L, Zhou C, Zhang S, Chen X, Liu J,
Xu F and Liang W: Chemotherapy reinforces anti-tumor immune
response and enhances clinical efficacy of immune checkpoint
inhibitors. Front Oncol. 12(939249)2022.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Joshi S and Sharabi A: Targeting
myeloid-derived suppressor cells to enhance natural killer
cell-based immunotherapy. Pharmacol Ther.
235(108114)2022.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Gainor JF, Shaw AT, Sequist LV, Fu X,
Azzoli CG, Piotrowska Z, Huynh TG, Zhao L, Fulton L, Schultz KR, et
al: EGFR mutations and ALK rearrangements are associated with low
response rates to PD-1 pathway blockade in Non-Small cell lung
cancer: A retrospective analysis. Clin Cancer Res. 22:4585–4593.
2016.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Ahn MJ, Yang J, Yu H, Saka H, Ramalingam
S, Goto K, Kim SW, Yang L, Walding A, Oxnard GR, et al: 136O:
Osimertinib combined with durvalumab in EGFR-mutant non-small cell
lung cancer: Results from the TATTON phase Ib trial. J Thorac
Oncol. 11(S115)2016.
|
|
73
|
Yang JC, Lee DH, Lee JS, Fan Y, De Marinis
F, Iwama E, Inoue T, Rodríguez-Cid J, Zhang L, Yang C-T, et al:
Phase III KEYNOTE-789 study of pemetrexed and platinum with or
without pembrolizumab for tyrosine kinase inhibitor-resistant,
EGFR-mutant, metastatic nonsquamous non-small cell lung cancer. J
Clin Oncol. 42:4029–4039. 2024.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Meador CB, Sequist LV and Piotrowska Z:
Targeting EGFR Exon 20 insertions in Non-small cell lung cancer:
Recent advances and clinical updates. Cancer Discov. 11:2145–2157.
2021.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Felip E, Cho BC, Gutiérrez V, Alip A,
Besse B, Lu S, Spira AI, Girard N, Califano R, Gadgeel SM, et al:
Amivantamab plus lazertinib versus osimertinib in first-line
EGFR-mutant advanced non-small-cell lung cancer with biomarkers of
high-risk disease: A secondary analysis from MARIPOSA. Ann Oncol.
35:805–816. 2024.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Zhang F, Liu H, Duan M, Wang G, Zhang Z,
Wang Y, Qian Y, Yang Z and Jiang X: Crosstalk among m6A RNA
methylation, hypoxia and metabolic reprogramming in TME: From
immunosuppressive microenvironment to clinical application. J
Hematol Oncol. 15(84)2022.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Villanueva N and Bazhenova L: New
strategies in immunotherapy for lung cancer: Beyond PD-1/PD-L1.
Ther Adv Respir Dis. 12(1753466618794133)2018.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Hay N: Reprogramming glucose metabolism in
cancer: Can it be exploited for cancer therapy? Nat Rev Cancer.
16:635–649. 2016.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Doroshow DB, Bhalla S, Beasley MB, Sholl
LM, Kerr KM, Gnjatic S, Wistuba II, Rimm DL, Tsao MS and Hirsch FR:
PD-L1 as a biomarker of response to immune-checkpoint inhibitors.
Nat Rev Clin Oncol. 18:345–362. 2021.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Ricciuti B, Wang X, Alessi JV, Rizvi H,
Mahadevan NR, Li YY, Polio A, Lindsay J, Umeton R, Sinha R, et al:
Association of high tumor mutation burden in non-small cell lung
cancers with increased immune infiltration and improved clinical
outcomes of PD-L1 blockade across PD-L1 expression levels. JAMA
Oncol. 8:1160–1168. 2022.PubMed/NCBI View Article : Google Scholar
|
|
81
|
McGrail DJ, Pilie PG, Rashid NU, Voorwerk
L, Slagter M, Kok M, Jonasch E, Khasraw M, Heimberger AB, Lim B, et
al: High tumor mutation burden fails to predict immune checkpoint
blockade response across all cancer types. Ann Oncol. 32:661–672.
2021.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Ayers M, Lunceford J, Nebozhyn M, Murphy
E, Loboda A, Kaufman DR, Albright A, Cheng JD, Kang SP, Shankaran
V, et al: IFN-γ-related mRNA profile predicts clinical response to
PD-1 blockade. J Clin Invest. 127:2930–2940. 2017.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Hu J, Coleman K, Zhang D, Lee EB, Kadara
H, Wang L and Li M: Deciphering tumor ecosystems at super
resolution from spatial transcriptomics with TESLA. Cell Syst.
14:404–417.e4. 2023.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Liu SY, Dong ZY, Wu SP, Xie Z, Yan LX, Li
YF, Yan HH, Su J, Yang JJ, Zhong WZ, et al: Clinical relevance of
PD-L1 expression and CD8+ T cells infiltration in patients with
EGFR-mutated and ALK-rearranged lung cancer. Lung Cancer.
125:86–92. 2018.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Rolfo C, Mack PC, Scagliotti GV, Baas P,
Barlesi F, Bivona TG, Herbst RS, Mok TS, Peled N, Pirker R, et al:
Liquid biopsy for advanced NSCLC: A consensus statement from the
international association for the study of lung cancer. J Thorac
Oncol. 16:1647–1662. 2021.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Kalluri R and LeBleu VS: The biology,
function, and biomedical applications of exosomes. Science.
367(eaau6977)2020.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Mino-Kenudson M, Schalper K, Cooper W,
Dacic S, Hirsch FR, Jain D, Lopez-Rios F, Tsao MS, Yatabe Y,
Beasley MB, et al: IASLC Pathology Committee. Predictive Biomarkers
for Immunotherapy in Lung Cancer: Perspective from the
International Association for the Study of Lung Cancer Pathology
Committee. J Thorac Oncol. 17:1335–1354. 2022.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Chen H, Jiang T, Yang Y, Cai G, Jiang Y
and Ouyang W: Exploring the carcinogenic potential of bisphenol A
in lung adenocarcinoma: Molecular mechanisms, key gene insights,
and immune microenvironment impacts. Front Immunol.
16(1647807)2025.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Ouyang W, Zhu C, Li Y, Huang H, Li F and
Ling L: Assessing the neurotoxic risks of triethyl citrate in daily
environmental exposure using network toxicology and molecular
docking. Ecotoxicol Environ Saf. 297(118225)2025.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Ouyang W, Peng Q, Lai Z, Huang H, Huang Z,
Xie X, Lin R, Wang Z, Yao H and Yu Y: Synergistic role of activated
CD4+ memory T cells and CXCL13 in augmenting cancer immunotherapy
efficacy. Heliyon. 10(e27151)2024.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Yu Y, Ouyang W, Huang Y, Huang H, Wang Z,
Jia X, Huang Z, Lin R, Zhu Y, Yalikun Y, et al: Artificial
intelligence-based multi-modal multi-tasks analysis reveals tumor
molecular heterogeneity, predicts preoperative lymph node
metastasis and prognosis in papillary thyroid carcinoma: A
retrospective study. Int J Surg. 111:839–856. 2025.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Ouyang W, Deng Z, Li Y, Chi W, Huang Z,
Zhan C, Li M, Wang D, Li F, Liu Y and Ling L: Traditional Chinese
medicine in cerebral infarction: Integrative strategies and future
directions. Phytomedicine. 143(156841)2025.PubMed/NCBI View Article : Google Scholar
|
|
93
|
O'Leary CL, Pierce N, Patel SP and Naidoo
J: Immune-related toxicity in non-small cell lung cancer: Current
state-of-the-art and future directions. J Thorac Oncol. 19:395–408.
2024.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Postow MA, Sidlow R and Hellmann MD:
Immune-related adverse events associated with immune checkpoint
blockade. N Engl J Med. 378:158–168. 2018.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Pasello G, Pavan A, De Nuzzo M, Frega S,
Ferro A, Dal Maso A, Bonanno L, Guarneri V and Girardi F:
Immune-related adverse events in patients treated with
immunotherapy for locally advanced or metastatic NSCLC in
real-world settings: a systematic review and meta-analysis. Front
Oncol. 14(1415470)2024.PubMed/NCBI View Article : Google Scholar : doi:
10.3389/fonc.2024.1415470.
|
|
96
|
Zhang W, Gu J, Bian C and Huang G:
Immune-related adverse events associated with immune checkpoint
inhibitors for advanced non-small cell lung cancer: A network
meta-analysis of randomized clinical trials. Front Pharmacol.
12(686876)2021.PubMed/NCBI View Article : Google Scholar
|
|
97
|
Schneider BJ, Naidoo J, Santomasso BD,
Lacchetti C, Adkins S, Anadkat M, Atkins MB, Brassil KJ, Caterino
JM, Chau I, et al: Management of immune-related adverse events in
patients treated with immune checkpoint inhibitor therapy: ASCO
guideline update. J Clin Oncol. 39:4073–4126. 2021.PubMed/NCBI View Article : Google Scholar
|
|
98
|
Lacouture ME, Sibaud V, Gerber PA, van den
Hurk CJ, Fernandez-Penas P, Santini D, Rueda A, Larocca C, Peris K,
Lacouture ME, et al: Prevention and management of dermatological
toxicities related to anticancer agents: ESMO Clinical Practice
Guidelines. Ann Oncol. 32:157–170. 2021.PubMed/NCBI View Article : Google Scholar
|
|
99
|
Thompson JA, Schneider BJ, Brahmer J, Zaid
MA, Achufusi A, Armand P, Berkenstock MK, Bermas Braaten T, Budde
LE, Chokshi S, et al: NCCN Guidelines Insights: Management of
immunotherapy-related toxicities, Version 2.2024. J Natl Compr Canc
Netw. 22:582–592. 2024.PubMed/NCBI View Article : Google Scholar
|
